Chase Therapeutics, founded in 2016 and based in Washington, DC, focuses on rapid translation of neuroscience discoveries into therapies for central nervous system disorders. Its lead programs are CTC-413 for Parkinson’s disease and CTC-501 for Major Depressive Disorder, both entering Phase 3 development. The company is also developing a companion diagnostic intended to identify Parkinson’s patients earlier and more accurately. Clinical data cited by the company indicate CTC-501 is well-tolerated and provides rapid symptomatic relief in MDD, while CTC-413 showed encouraging proof-of-concept results with symptom mitigation and signs of neuroprotective potential. Chase plans to advance these programs and the diagnostic into pivotal trials supported by recent financing.

Total raised

$20M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2021